- Home
- GOSS vs ECX Comparison
GOSS vs ECX Comparison
Compare GOSS & ECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GOSS | ECX |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 726.8M | 643.6M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | GOSS | ECX |
|---|---|---|
| Price | $3.57 | $1.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $8.60 | $3.20 |
| AVG Volume (30 Days) | ★ 3.3M | 2.8M |
| Earning Date | 11-05-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $44,051,000.00 | ★ $822,663,229.00 |
| Revenue This Year | N/A | $772.81 |
| Revenue Next Year | $6.41 | $30.47 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 6.99 |
| 52 Week Low | $0.76 | $0.76 |
| 52 Week High | $3.87 | $3.25 |
Technical Indicators
Market Signals| Indicator | GOSS | ECX |
|---|---|---|
| Relative Strength Index (RSI) | 56.81 | 46.53 |
| Support Level | $3.53 | $1.60 |
| Resistance Level | $3.87 | $2.16 |
| Average True Range (ATR) | 0.24 | 0.13 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 51.96 | 37.20 |
Price Performance
Historical ComparisonAbout GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About ECX ECARX Holdings Inc. Ordinary shares
ECARX Holdings Inc is engaged in the sales of system-on-chip core modules, automotive computing platform products, and software stacks as well as the provision of research and development services in the People's Republic of China. The company's core products include infotainment head units, digital cockpits, vehicle chip-set solutions, a core operating system, and an integrated software stack. Beyond this, ECARX is developing a full-stack automotive computing platform. It is engaged in automotive intelligence and networking.